Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists
Hiroyuki Kai(Futaba (Japan)), Noriyuki Kurose(Shionogi (Japan)), Takayuki Kameyma(Shionogi (Japan)), Kenichiroh Nakamura(Shionogi (Japan)), Keiichiro Hirai(Shionogi (Japan)), Yuki Murakami(Doshisha University), Sosuke Yoneda(Shionogi (Japan)), Yusuke Ichihashi(Shionogi (Japan)), Tohru Horiguchi(Shionogi (Japan)), Hiroko Ogawa(Shionogi (Japan)), Naohiro Itoh(Shionogi (Japan)), Ryouko Sekimoto(Shionogi (Japan)), Erika Kasai(Shionogi (Japan)), Osamu Yoshida(Ehime University Hospital), Yasuhiko Fujii(Tokyo Institute of Technology), Kazuhisa Minami(Shionogi (Japan)), Takuya Shintani(Osaka University), Shunji Shinohara(Shionogi (Japan)), Naohiro Onodera(Shionogi (Japan))
Cited by 28
Related Papers
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388
Detection of urovirulence factors in<i>Escherichia coli</i>by multiplex polymerase chain reaction
|FEMS Immunology & Medical Microbiology|1995|317
Genetic Evidence Supporting the Fecal-Perineal-Urethral Hypothesis in Cystitis Caused by Escherichia Coli
|The Journal of Urology|1997|281